Discovery of a potent thiadiazole class of histamine H 3 receptor antagonist for the treatment of diabetes

ACS Medicinal Chemistry Letters

Volumn 3, Issue 3, 2012, Pages 198-202

  Rao, Ashwin U ^a   Shao, Ning ^a   Aslanian, Robert G ^a   Chan, Tin Yau ^a   Degrado, Sylvia J ^a   Wang, Li ^a   McKittrick, Brian ^a   Senior, Mary ^a   West, Robert E ^b   Williams, Shirley M ^b   Wu, Ren Long ^b   Hwa, Joyce ^b   Patel, Bhuneshwari ^b   Zheng, Shuqin ^b   Sondey, Christopher ^b   Palani, Anandan ^a  

^a Department of Medicinal Chemistry ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

antagonist; H3; HbA 1c; Histamine; non fasting glucose; thiadiazole; type 2 diabetes

Indexed keywords

4 [5 [(1,4' BIPIPERIDIN) 1' YL] 1,3,4 THIADIAZOL 2 YL] 2 (PYRIDIN 2 YL)MORPHOLINE; DRUG VEHICLE; GLUCOSE; HEMOGLOBIN A1C; HISTAMINE H3 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; STREPTOZOCIN DIABETES;

MUS;

EID: 84863229168     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200250t     Document Type: Article

References (37)

1. 3) of histamine receptor Nature 1983, 302, 832-837 (Pubitemid 13125123)
2. 3 heteroreceptors Fundam. Clin. Pharmacol. 1994, 8, 128-137 (Pubitemid 24103046)
3. 3 receptor subtypes Br. J. Pharmacol. 1992, 107, 919-923
4. Haas, H.; Panula, P. The role of histamine and the tuberomamillary nucleus in the nervous system Nature Rev. Neurosci. 2003, 4, 121-130 (Pubitemid 37271382)
5. 3 receptor drugs Nat. Rev. Drug Discovery 2005, 4, 107-120 (Pubitemid 40277492)
6. 3 receptor antagonists reach out for the clinic Drug Discovery Today 2005, 10, 1613-1627 (Pubitemid 41817610)
7. 4 expressed in bone marrow Mol. Pharmacol. 2001, 59, 420-426 (Pubitemid 32179918)
8. Hough, L. B. Genomics meets histamine receptors: new subtypes, new receptors Mol. Pharmacol. 2001, 59, 415-419 (Pubitemid 32179917)
9. Brown, R. E.; Stevens, D. R.; Haas, H. L. The physiology of brain histamine Prog. Neurobiol. 2001, 63, 637-672 (Pubitemid 32119421)
10. Oades, R. D. Attention deficit disorder with hyperactivity (ADDH): The contribution of catecholaminergic activity Prog. Neurobiol. 1987, 29, 365-391
11. Velligan, D. I.; Miller, A. L. Cognitive dysfunction in schizophrenia and its importance to outcome: The place of atypical antipsychotics in treatment J. Clin. Psychiatry 1999, 60, 25-28
12. 3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders Mol. Interventions 2006, 6, 77-88
13. 3 receptor agonists and antagonists Trends Pharmacol. Sci. 1998, 19, 177-183 (Pubitemid 28255404)
14. 3 receptor antagonists Drugs Future 1996, 21, 507-520
15. 3 receptor as a therapeutic drug target for CNS disorders Drug Discovery Today 2009, 14, 509-515
16. Monti, J. M. Involvement of histamine in the control of the waking state Life Sci. 1993, 53, 1331-1338
17. 3 receptor antagonists/inverse agonists as anti-obesity agents Curr. Opin. Invest. Drugs 2003, 4, 1190-1197 (Pubitemid 37420105)
18. 3 antagonists in models of obesity Inflammation Res. 2004, 53, S47-S48
19. 3 antagonists/inverse agonists Biochem. Pharmacol. 2006, 71, 1103-1113 (Pubitemid 43361919)
20. 3 receptor decreases caloric intake in higher mammalian species Biochem. Pharmacol. 2007, 73, 1237-1242 (Pubitemid 46413184)
21. 3 receptor protean agonist proxyfan J. Endocrinol. 2011, 152, 828-835
22. Hancock, A. A.; Brune, M. E. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists Expert Opin. Invest. Drugs 2005, 14, 223-241 (Pubitemid 40520963)
23. Sandoval, D. A.; Obici, S.; Seeley, R. J. Targeting the CNS to treat type 2 diabetes Nat. Rev. Drug Discovery 2009, 8, 386-398
24. Ishizuka, T.; Hatano, K.; Murotani, T.; Yamatodani, A. Comparison of the effect of an H(3)-inverse agonist on energy intake and hypothalamic histamine release in normal mice and leptin resistant mice with high fat diet-induced obesity Behav. Brain Res. 2008, 188, 250-254
25. 3 receptor antagonists Mini Rev. Med. Chem. 2004, 965-977 (Pubitemid 39406256)
26. Lin, J.; Lu, A. Y. H. Inhibition and induction of cytochrome P450 and the clinical implications Clin. Pharmacokinet. 1998, 35, 361-390 (Pubitemid 28520008)
27. 3 receptor antagonists and antipsychotic drugs Brain Res. 2005, 1045, 142-149 (Pubitemid 40725230)
28. 3 antagonists Mini Rev. Med. Chem. 2004, 979-992 (Pubitemid 39406257)
29. 3 antagonists Expert Opin. Ther. Patents 2007, 17, 675-687 (Pubitemid 47045530)
30. 3 receptor ligands break ground in a remarkable plethora of therapeutic areas Expert Opin. Invest. Drugs 2007, 16, 967-985 (Pubitemid 47074155)
31. 3 receptor as drug discovery target J. Med. Chem. 2011, 54, 26-53
32. 3 receptor antagonists/inverse agonists Expert Opin. Ther. Patents 2011, 20, 1147-1169
33. 3 receptor antagonists Bioorg. Med. Chem. Lett. 2009, 19, 6176-6180
34. Palani, A.; Berlin, M. Y.; Aslanian, R. G.; Vaccaro, H. M.; Chan, T.-Y.; Xiao, D.; Degrado, S.; Rao, A. U.; Chen, X.; Lee, Y. J.; Sofolarides, M. J.; Shao, N.; Huang, Y. R.; Liu, Z.; Wang, L. Y.; Pu, H. Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof. Patent WO 2010045303, 2010.
35. 3 antagonists Bioorg. Med. Chem. Lett. 2011, 21, 861-864
36. Sorota, S.; Zhang, X.-S.; Margulis, M.; Tucker, K.; Priestley, T. Characterization of a hERG screen using the IonWorks HT: Comparison to a hERG rubidium efflux screen Assay Drug Dev. Technol. 2005, 3, 47-57 (Pubitemid 40533252)
37. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E.; Kasman, I. N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olsen, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of p-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the mdr1a/1b knockout mouse model Drug Metab. Dispos. 2005, 33, 165-174 (Pubitemid 40023528)